Protocol Ledger

NCT07153445 · Phase II · RECRUITING

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

Interventional Phase II clinical trial protocol NCT07153445 sponsored by Fundación GECP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-08 Enrollment: 97 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07153445
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)97 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07153445
Protocol FieldVerified Registry Value
NCT IdentifierNCT07153445
Consolidated Lead SponsorFundación GECP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment97 participants (ESTIMATED)
Registered Start Date2025-07-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07153445
Hospital Research SiteLocationSite Profile
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->
Hospital de La Santa Creu I Sant PauBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI